Other Events · Jun 4, 2026Immutep to present positive interim Phase I data for first-in-class LAG-3 agonist antibody IMP761 at EULAR 2026IMMPIMMUTEP LtdImmutep Limited announced that it will present positive interim Phase I data for its first-in-class LAG-3 agonist antibody, IMP761, at the EULAR 2026 conference. No specific financial or clinical figures were provided in the filing.
